公司從事藥物開發和商業化的醫院治療中樞神經係統(CNS)疾病和血栓性心血管疾病、適應症,有大量的未滿足的醫療需要。

Humanetics臨床分期製藥公司從事開發和商業化的產品來提高人類健康和福祉市場緊急和未滿足的需求。專注於為腫瘤輻射調節器,醫學成像和醫學對策的用途。300年公司開發生物,一個高度選擇性調製器的炎症、細胞周期阻滯和DNA損傷修複。Humanetics成立於1988年,總部設在明尼阿波利斯,明尼蘇達州。

Richwood發展中樞神經係統疾病的藥物,尤其是兒童多動症。

Cervelo製藥是一個semi-virtual臨床開發公司成立於2006年。,公司的重點在於的許可證和發展中期階段神經學小分子藥物的候選人。目前在全球擁有獨家權利為所有跡象表明小分子,第一次在課堂上,藥物的候選人,演示了一個安全的和潛在的有效能力對神經性和炎性疼痛,以及炎症。

Indena是一家致力於識別、開發和生產的活動原則來源於植物,用於製藥、保健食品和化妝品行業。Indena、民營意大利公司約有700名員工,其中包括10%致力於全職研究,旨在培養管理,製造、分銷業務在全世界40多個國家。Indena成功的關鍵是它的研究,包括:藥用植物的藥理篩選的好處;識別新的活躍的原則;提取和純化係統的開發和工業應用的前沿。phyto-chemical研究進行Indena Settala自己的研究中心,意大利。Indena同樣也與世界上最著名的大學和私人研究機構在生物的安全性和有效性臨床評估階段i的主要戰略目標之一的醫藥研究開發新的積極的原則的應用程序。這也是一個不可缺少的保健食品和化妝品行業的基礎。在製藥行業Indena目前專注於抗癌治療的發展,紫杉醇的成功後,以及在抗菌和抗病毒藥物。還在研究是活躍的原則治療病態和中樞神經係統功能障礙,如抑鬱,焦慮,陽痿,睡眠障礙、感覺過敏。 Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Neuraltus製藥是一家民營生物製藥公司,致力於開發和商業化創新療法,解決關鍵的未滿足的需求對病人和醫生在神經退行性疾病的治療。公司與全球合作ALS專家和尋求輸入病人倡導組織幫助通知臨床發展道路和更好地理解需求的人受到疾病的影響。